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Luminescent lanthanide chelates have been used to label antibodies in time-gated luminescence (TGL) 
bioimaging. However, it is a challenging task to label directly an antibody with lanthanide-binding 
ligands and achieve control of the target ligand/protein ratios whilst ensuring that affinity and avidity 
of the antibody remain uncompromised. We report the development of a new indirect detection 
reagent to label antibodies with detectable luminescence that circumvents this problem by labelling 
available lysine residues in the linker portion of the recombinant fusion protein Linker-Protein G (LPG). 
Succinimide-activated lanthanide chelating ligands were attached to lysine residues in LPG and Protein 
G (without Linker) and the resulting Luminescence-Activating (LA-) conjugates were compared for 
total incorporation and conjugation efficiency. A higher and more efficient incorporation of ligands 
at three different molar ratios was observed for LPG and this effect was attributed to the presence 
of eight readily available lysine residues in the linker region of LPG. These Luminescence-Activating 
(LA-) complexes were subsequently shown to impart luminescence (upon formation of europium(III) 
complexes) to cell-specific antibodies within seconds and without the need for any complicated 
bioconjugation procedures. The potential of this technology was demonstrated by direct labelling of 
Giardia cysts and Cryptosporidium oocysts in TGL bioimaging.
Lanthanide (e.g., Eu3+, Tb3+) ions are of growing interest as luminescent probes for time-gated luminescence 
(TGL) bioimaging1. The outstanding luminescent properties of lanthanide ions are characterised by their sharp 
emission profiles (< 10 nm width), large Stokes shifts (> 150 nm) and long (millisecond) excited-state lifetimes. 
These features, in conjunction with pulsed excitation and time-gated measurements, allow temporal discrimi-
nation against fast decaying (nanosecond) autofluorescence and scattered excitation light2. TGL microscopy has 
been used successfully to visualise biomolecules and cells in autofluorescent environments3 by exploiting the long 
luminescent lifetimes of lanthanide ions.
Trivalent lanthanide ions (Ln3+) have intrinsically low absorption cross-sections, thus direct excitation yields 
only low levels of luminescence. As a result, lanthanide ions need to be excited indirectly through a method 
known as sensitisation, where a lanthanide ion is chelated by an organic ligand containing a chromophore that 
acts as an antenna to sensitise the absorption of light and transfer of excitation energy to the chelated ion, result-
ing in higher luminescence and extended emission lifetimes4. This construction is referred to as a lanthanide 
chelate. Ligands capable of lanthanide binding can be attached to a biomolecule (e.g., antibodies and nucleic 
acids) via a cross-linking group.
A number of highly luminescent tetradentate bis β-diketonate-Eu3+ chelates have been used to label 
antibodies in TGL bioimaging (e.g., 4,4′ -bis(1″ ,1″ ,1″ ,2″ ,2″ ,3″ ,3″ -heptafluoro-4″ ,6″ -hexanedion-6″ 
-yl)-chlorosulfo-o-terphenyl (BHHCT)5 and 4,4-bis-(1″ ,1″ ,1″ ,2″ ,2″ ,3″ ,3″ -heptafluoro-4″ ,6″ -hexanedion-6″ -yl) 
sulfonylaminopropyl-ester-N-succinimide-ester-o-terphenyl (BHHST)6, but the difficulties associated with 
the direct incorporation of lanthanide chelates onto antibodies (via the initial attachment of the lanthanide 
ion-binding ligands) are well documented. For example, BHHCT is known to cause antibody inactivation or 
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precipitation due to poor aqueous solubility, over-conjugation of ligand to the antibody, and variations in antibody 
reactivity and sensitivity6,7. Hence, direct antibody modification is often inefficient and requires time-consuming 
optimisation, a process unique to a given antibody. Indirect methods that deliver sufficient luminescent signal 
with retention of antibody function have been established. For example, Connally et al.6 applied BHHST-labelled 
secondary antibodies for the indirect detection of Giardia with TGL microscopy but direct modification of a sec-
ondary antibody makes it susceptible to inactivation in the same fashion as directly labelling a primary antibody. 
Alternatively, lanthanide-labelled streptavidin has been used as an indirect detection reagent to label biotinylated 
secondary antibodies with detectable luminescence for TGL bioimaging8. Even so, this method requires the spe-
cific modification of antibodies with biotin and relies on the biotin-streptavidin binding interaction, which can be 
difficult to control. Streptavidin conjugated proteins have also the tendency of binding non-specifically to bioti-
nylated proteins in mammalian cells resulting in unpredictable background problems9–11. Additional chelates can 
be loaded onto a carrier molecule that tolerates a high degree of labelling and can be chemically cross-linked to a 
detection reagent to maximise luminescence further. For example, streptavidin typically is conjugated to bovine 
serum albumin (BSA), and then the conjugate is labelled with lanthanide chelates prior to use as an indirect 
detection reagent in TGL bioimaging1,12–14.
Another potential universal detection reagent is the recombinant fusion protein, Linker-Protein G (LPG), the 
subject of this report. LPG contains two functionally distinct regions; (a) a peptide linker sequence which has 
specific binding affinity towards silica-containing materials, and (b) Streptococcus Protein G′ which has specific 
binding affinity towards antibodies15. LPG has been used as an anchor point for the oriented immobilisation 
of antibodies onto silica-containing materials without the need for complex surface chemical modification15–19. 
In addition, the linker region of LPG presents itself as a prospective lanthanide carrier. It contains a number of 
accessible lysine residues whose terminal amino groups provide binding sites for succinimide-activated ligands 
capable of binding europium(III), ultimately allowing the addition of multiple luminophores with minimal effect 
on the antibody-binding ability of the Protein G region.
4,4′ -Bis(1″ ,1″ ,1″ ,2″ ,2″ ,3″ ,3″ -heptafluoro-4″ ,6″ -hexanedion-6″ -yl)sulfo-o-terphenyl-tetraethylene 
glycol-N-hydroxysuccinimide (BHHTEGST)20 is a newly developed tetradentate bis β-diketone-ligand derived 
from BHHST6 and BHHCT21, capable of binding europium(III). It has good aqueous solubility, excellent lumines-
cent output (when complexed with europium(III)) and a mild succinimide reactive group that facilitates covalent 
attachment to biomolecules that contain lysine residues. BHHTEGST also possesses an extended tetraethylene 
glycol tether that projects its hydrophobic europium(III) binding moiety (BHHCT) away from the modified pro-
tein to prevent adverse interactions and enhance conjugate solubility.
In this communication, we show that LPG labelled with BHHTEGST serves as an effective indirect detection 
reagent to impart luminescence rapidly to antibodies for TGL bioimaging. We demonstrate also that the presence 
of the linker region significantly increases luminescent output, enabling rapid and simple visualisation of Giardia 
cysts and Cryptosporidium oocysts under time-gated conditions.
Results
Conjugation of PG (without Linker) and LPG with BHHTEGST. PG and LPG must be able to with-
stand extensive conjugation with the BHHTEGST ligand and retain their capacity to bind antibodies for use as 
universal detection reagents in TGL bioimaging. Thus, each protein underwent conjugation reactions at different 
BHHTEGST:Lysine ratios, yielding a total of three Luminescence-Activating (LA-) conjugates (Table 1), which 
will be referred to in this manuscript as LA-PGHIGH, MID or LOW and LA-LPGHIGH, MID or LOW. The average number 
Figure 1. Illustration showing the luminescent labelling of cells using LA-PG- and LA-LPG-coupled 
antibodies. Coupling of LA-PG (A) or LA-LPG (B) to an antibody results in a “LA-PG or LA-LPG–Antibody” 
conjugate that can be used to label a target cell with luminescence upon exposure to Eu3+. The red stars 
represent an unspecific number of BHHTEGST ligands incorporated onto the LA-PG (A) or LA-LPG (B) 
biomolecule.
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of ligands attached to LA-PG or LA-LPG at each conjugation ratio was then semi-quantified as described in the 
Materials and Methods section and the results are summarised in Table 1.
The BHHTEGST ligand is amine reactive and attaches covalently to lysine residues in target proteins. PG 
contains 19 lysine residues whereas LPG has 27 due to the presence of an additional 8 lysines located in the 
linker region. Therefore it was expected that LPG would be conjugated with a higher number of ligands at each 
BHHTEGST:Lysine ratio tested. As shown in Table 1, in conjugations performed at the lowest BHHTEGST:Lysine 
ratio, PG was modified with only an average of 4.3 ligands whereas LPG had 12.3. This difference (8 ligands) 
correlates with the additional eight ligands present on the linker region of LPG. A similar difference (7.1 ligands) 
in the number of attached ligands was observed at the mid BHHTEGST:Lysine ratio, in which PG and LPG 
contained on average 9.7 and 16.8 ligands, respectively. However, this difference was considerably smaller (2.5 
ligands) at the highest BHHTEGST:Lysine ratio tested, which resulted in PG and LPG complexes that contained 
on average 15.5 and 18.0 BHHTEGST ligands, respectively. These results show that better and more consistent 
conjugation efficiencies were achieved with LPG (45.7–66.7%) compared to PG (22.8–81.6%) across the range 
of BHHTEGST:Lysine ratios tested. More importantly, the results of the conjugation studies at low and medium 
levels suggest that the incorporation of the additional BHHTEGST ligands (8 and 7.1, respectively) takes place 
preferentially on the linker region of LPG, remote from the antibody-binding region.
Using lanthanide-activated complexes to label Giardia and Cryptosporidium. We investigated 
whether the lanthanide-activated complexes could act as universal detection reagents to impart detectable lumi-
nescence to primary antibodies without compromising their function and which conjugation ratio was the most 
effective. Using the strategy illustrated in Fig. 1, each of the modified conjugates from the previous section was 
coupled to cell-specific antibodies for the luminescent labelling of Giardia cysts (Fig. 2A) and Cryptosporidium 
oocysts (Fig. 2B), following exposure of slides to a europium(III) solution. The labelled cells were visualised by 
TGL microscopy using a Gated Auto-synchronous Luminescence Detector (GALD)3 and the SNRs from the raw 
digital images were calculated using ImageJ software (Table 2).
Of all the complexes studied (Fig. 2), LA-LPGMID images showed high definition and SNRs of 76 for Giardia 
and 71 for Cryptosporidium (Table 2). In contrast, the cells labelled with the LA-PGMID complex exhibited low 
luminescence and poor resolution. Accordingly, the SNRs in these images were significantly lower for both 
cell-types (Giardia = 7; Cryptosporidium = 16). The LA-LPGMID complex provided more than a 10-fold enhance-
ment in the SNRs of labelled Giardia luminescence and more than a 4-fold enhancement for Cryptosporidium 
when compared to LA-PGMID. Cells labelled with LA-LPGHIGH displayed similar SNRs (Giardia = 72; 
Cryptosporidium = 76) to those shown by LA-LPGMID. However, the cells appeared oversaturated with 
poorly-defined boundaries. The LA-PGHIGH control generated low SNRs (Giardia = 16; Cryptosporidium = 21) 
and produced images that showed weak luminescence and low resolution. In comparison to LA-PGHIGH, the 
LA-LPGHIGH complex improved the SNRs of the labelled Giardia and Cryptosporidium by more than 4-fold and 
3-fold, respectively. Low SNRs were obtained from cells labelled with the LA-LPGLOW complex (Giardia = 20; 
Cryptosporidium = 25) and the cells showed very weak luminescent output and poor definition with the weakest 
SNRs produced by cells labelled with LA-PGLOW (Giardia = 6; Cryptosporidium = 10). In these images the cells 
were difficult to detect and identify. When compared to LA-PGLOW, the LA-LPGLOW complex amplified SNRs by 
more than 3-fold and 2-fold for labelled Giardia and Cryptosporidium, respectively.
These results indicated that all of the modified complexes can bind antibodies and render them lumines-
cent, but with greatly varied efficacy. The cells labelled with LA-LPG were significantly brighter in label inten-
sity than LA-PG (irrespective of the conjugation concentration) an observation that can be attributed to the 
higher BHHTEGST content of the LA-LPG conjugates (see Table 1) and hence, europium(III) chelates. However, 
LA-LPGHIGH possesses the highest BHHTEGST content and produced images in which cells were highly lumines-
cent but poorly defined. This lack of definition could possibly be due to a reduction in cell targeting efficiency. The 
LA-LPGMID conjugate provided clear, high-contrast and definition images, making it the best detection reagent 
under these conditions for the attachment to the antibodies tested. Therefore, all subsequent cell-labelling exper-
iments were performed using LA-LPGMID-coupled antibodies.
Detection of cells in autofluorescent environments. Lanthanide chelates have long luminescence 
lifetimes that enable temporal discrimination of shorter-lived autofluorescence, unlike conventional fluoro-
phores. We tested whether LA-LPGMID-coupled antibodies in conjunction with TGL microscopy can be used 
for background-free detection of cells in autofluorescent environments (Fig. 3). In an initial control experiment, 
the LA-LPGMID complex was coupled to a FITC-conjugated antibody (CRY104-FITC) specific for the cell walls 
Conjugation ratio
Relative number of ligands BHHTEGST:Lysine ratioa
LA-PG CE (%)b LA-LPG CE (%) LA-PG LA-LPG
High 15.5 ± 1.4 81.6 ± 7.3 18.0 ± 0.7 66.7 ± 0.7 1.5 1.6
Mid 9.7 ± 2.8 51.2 ± 14.8 16.8 ± 0.6 62.1 ± 0.6 0.7 0.8
Low 4.3 ± 0.6 22.8 ± 3.1 12.3 ± 0.2 45.7 ± 0.2 0.4 0.4
Table 1.  Semi-quantification of the number of BHHTEGST ligands attached to PG and LPG after 
conjugation reactions were performed in triplicate with BHHTEGST:Lysine ratios between 1.6-0.4. 
aBHHTEGST:Lysine ratio is the number of moles of BHHTEGST added per lysine residue in each protein. 
bCE = Conjugation Efficiency (%) of total lysine residues modified with BHHTEGST).
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of Cryptosporidium oocysts. Cells were then labelled and visualised by either fluorescence microscopy or TGL 
microscopy. Cells observed in the fluorescent FITC channel displayed bright green fluorescence and good defi-
nition (Fig. 3b).
Under time-gated conditions the cells emitted red luminescence and maintained their definition (Fig. 3c). 
These results indicated that LA-LPGMID can be coupled easily to a different fluorophore-conjugated antibody and 
Figure 2. Luminescent labelling of (A) Giardia cysts and (B) Cryptosporidium oocysts using (a–f)  
LA-PGHIGH, MID, or LOW or (g–l) LA-LPGHIGH, MID, or LOW -coupled antibodies. (a, c, e and h, j, l) Bright-field 
microscopy. (b, d, f and g, i, k) TGL microscopy. Exposure time for TGL microscopy was identical for all 
samples; as a result the brightness of the images are relative to each other.
Conjugation ratio
Signal-to-Noise ratios
Giardia cysts Cryptosporidium oocysts
LA-PG LA-LPG Fold diff.a LA-PG LA-LPG Fold diff.
High 16 72 4.5 21 76 3.6
Mid 7 76 10.9 16 71 4.4
Low 6 20 3.3 10 25 2.5
Table 2.  Signal to noise ratios (SNRs) for Giardia cysts (Fig. 2A) and Cryptosporidium oocysts (Fig. 2B) 
labelled with each of the LA-PG and LA-LPG complexes. SNR analysis of raw image data was performed 
using ImageJ software. aFold diff. = Fold difference.
Figure 3. Cryptosporidium oocysts labelled with “LA-LPGMID + CRY104-FITC” complex. (a) Bright field 
(b) FITC channel (c) TGL conditions.
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applied as a dual-immuno-labelling technique based on emission lifetimes. Consequently, we used this meth-
odology to compare the efficiency of a conventional fluorophore (FITC) and our lanthanide-carrier molecule 
(LA-LPGMID) to label cells in an autofluorescent environment (Fig. 4). Cryptosporidium oocysts were mixed with 
a sample of autofluorescent Synechococcus cells and then labelled with the “LA-LPGMID + CRY104-FITC” com-
plex (that was used to obtain the images in Fig. 3). The Cryptosporidium oocysts were fluorescent green in the 
FITC channel as expected, but difficult to discriminate against background autofluorescence provided by the 
Synechococcus cells (Fig. 4a). Switching to time-gated microscopy suppressed the background autofluorescence 
and generated high-contrast images in which cells exhibited red luminescence and were identified readily against 
a fluorescence-free background (Fig. 4b). These results show that the LA-LPGMID complex in combination with 
TGL microscopy can be used successfully for the sensitive detection of cell targets in the presence of background 
autofluorescence.
Discussion
We labelled the lysine residues within PG and LPG with three different molar ratios of BHHTEGST and observed 
different levels of incorporation (Table 1). Overall, LA-LPG had a greater number of attached BHHTEGST lig-
ands than LA-PG at each ratio tested. The conjugation efficiency of LA-PG decreased almost proportionality to 
the molar ratio of BHHTEGST, whereas LA-LPG underwent less obvious reductions in conjugation efficiency as 
the molar ratio of BHHTEGST was lowered. Such differences may be explained by variations in lysine content 
and accessibility of lysine residues on the linker and Protein G regions. The linker accounts for ~30% of the lysine 
residues on LPG and can be modified with up to 8 amine-reactive ligands. The intrinsic structural disorder of 
the linker19 may allow it to undergo conformational changes that enable interaction between its lysine residues 
and BHHTEGST, such that ligand attachment in this linker region is favoured at lower molarities in compar-
ison with attachment at lysines residues on the Protein G component. In contrast, PG has a highly stable and 
ordered structure. PG also retains its activity at extreme temperatures and across a wide range of pH values. High 
concentrations of denaturant are required to unfold the protein22. The IgG-binding domains of PG have struc-
tural homology with the rigid and inflexible protein, ubiquitin23. Thus, unlike the linker, the PG region cannot 
extensively alter its conformation to interact readily with BHHTEGST, preventing high levels of incorporation at 
lower molarities. Further analysis of the amino acid sequence of LPG using a neural network predictor of natural 
disordered regions (PONDR, http://pondr.com) was performed (results not shown). It identified the ordered 
structure of the Fc-binding domains within PG and confirmed the disordered structure of the linker region. We 
compared the relative SNRs of Giardia cysts and Cryptosporidium oocysts that were labelled with either LA-PG or 
LA-LPG complexes (Table 2) to determine which LA-complexes were the most compatible for TGL bioimaging. 
We found that cells labelled with LA-PG complexes exhibited weak luminescence that was unacceptable for TGL 
microscopy. Conversely, cells labelled with LA-LPG complexes displayed up to 10-fold higher SNRs. This result 
shows that the linker region can act as an effective lanthanide-carrier portion of the LPG molecule that is capable 
of bearing additional chelates to increase the luminescent output of LPG for TGL bioimaging applications.
LA-LPGMID provided bright, high-contrast and high-definition images, making it the best LA-complex for 
indirect detection in TGL bioimaging. It contains approximately seventeen BHHTEGST ligands (Table 1), if 
the eight lysine residues on the linker are preferentially modified (as discussed above) then the remaining nine 
BHHTEGST ligands are likely to be located on the PG region. Markela et al.24 reported that Protein G retained 
optimal affinity and binding specificity for IgGs when labelled with up to nine europium chelates. The results with 
the LA-LPGMID complex highlight the linker’s ability to impart high luminescence to a detection reagent without 
affecting its binding avidity and specificity.
A loss in binding specificity generally occurs when the detection reagent is over-modified1. In this study, the 
LA-LPGHIGH complex had the highest BHHTEGST ligand content and produced cellular images with high SNRs, 
Figure 4. A sample of Cryptosporidium oocysts was spiked with autofluorescent Synechococcus cells 
and then labelled with “LA-LPGMID + CRY104-FITC” complex. (a) Bright field (b) FITC channel (c) TGL 
conditions.
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but the labelled cells were poorly defined and a large amount of non-specific binding was observed. We propose 
that this lack of specificity is due to the over-modification of LA-LPGHIGH reducing its affinity towards antibodies. 
The over-modification of antibody-binding proteins (ABPs) with lanthanide chelates has been observed to reduce 
their antibody-binding affinity24–27. For example, the attachment of chelates to just 15% of the available lysine res-
idues on Protein A results in ~50% loss in its binding affinity25. Furthermore, the attachment of different chelate 
types can vary the affinity of ABPs towards antibodies from different species27.
The BHHTEGST ligand is a molecule that becomes covalently attached to proteins via lysine amino groups. 
The truncated variant of PG28 used here includes two domains with high affinity towards the Fc region of IgGs29. 
Both domains consist of a four-stranded β-sheet crossed diagonally by a single α-helix. X-ray crystallography23 
and site-directed mutagenesis studies30 have identified two lysine residues at the centre of the α-helix that are 
integral to the IgG-binding interaction. Therefore, preservation of the four lysine residues on the α-helices of the 
two IgG-binding domains of PG is essential for optimum binding affinity and specificity. We used a protein model 
that depicts an IgG-binding domain (i.e., the C2 domain) from Protein G in complex with the Fc region of human 
IgG (PDB - 1FCC; Fig. 5) to investigate further the potential impact of BHHTEGST incorporation into PG or 
LPG. In this model, BHHTEGST-Eu3+ chelates were attached to the two lysines present on the α-helix of the 
IgG-binding domain that participate in antibody-binding. Both of the relatively large BHHTEGST-Eu3+ chelates 
were shown to project from this domain through the entire Fc region of the bound human IgG. Therefore, any 
modification of these residues with BHHTEGST could sterically hinder the binding interactions between PG and 
antibodies. With LPG the accessibility and preferential modification of lysine residues within the linker region 
positions the BHHTEGST ligands away from the antibody-binding region (PG), thus reducing the potential 
modification of residues that mediate antibody-binding.
TGL bioimaging has relied on lanthanide-labelled streptavidin as an indirect detection reagent to deliver 
sufficient luminescence to antibodies without impeding their biological function8. This methodology requires 
the modification of secondary antibodies with biotin and cell-labelling procedures can take up to 24 h1,8,12–14. 
As an alternative, ABPs such as Protein G and Protein A, rapidly bind with high affinity and specificity to a 
broad spectrum of IgG species and subclasses without influencing their capacity to recognise and bind antigens29. 
ABPs labelled with lanthanide chelates have been used in the past as detection reagents for indirect time-resolved 
fluoroimmunoassays (TR-FIA)24,31,32. We have shown that LA-PG and LA-LPG complexes can be used as indirect 
detection reagents for TGL bioimaging and impart luminescence to antibodies within seconds and without the 
need for antibody-modification. It should be noted that Protein G labelled with lanthanide chelates are commer-
cially available as an indirect detection reagent for TR-FIA in the dissociative enhancement format (DELFIA)24. 
In this method, a protein is labelled with non-photoactive chelates that bind lanthanide ions. The ions are then 
dissociated and released into an enhancement solution in which they become luminescent and can be detected. 
Unfortunately this method is incompatible with TGL microscopy because spatial resolution would be lost in a 
dissociation-enhanced format. For this reason, TGL microscopy requires detection reagents to contain intrinsi-
cally luminescent lanthanide chelates (e.g., tetradentate bis β-diketonate-Eu3+ chelates) to label bio-targets effec-
tively1,5,8,12–14,33. Although ABPs labelled with conventional fluorophores (e.g., FITC and Alexa Fluor) are available 
commercially for use as indirect detection reagents in fluorescence microscopy, we are not aware of any reports in 
which ABPs have been labelled with intrinsically luminescent chelates for TGL microscopy.
Typically, indirect detection reagents are cross-linked to carrier molecules and the resulting conjugate 
(e.g., SA-BSA) is then labelled with luminescent chelates1,5,12–14,33 allowing higher luminescence for TGL bio-
imaging to be achieved. In some cases detection reagents have been protein engineered to substitute a small 
number of surface residues with lysines to improve chelate incorporation34. Here we investigated whether the 
linker region of LPG could serve as a carrier segment for BHHTEGST ligands and subsequent europium(III) 
chelation. Conventional carrier molecules often reduce the specificity of the detection reagent to which they 
are cross-linked35. For example, Ius et al.25 described a 55% loss in the IgG-binding affinity of Protein A after 
Figure 5. Protein structure models of an IgG-binding domain (C2) from Protein G (blue) in complex with 
the Fc-region of human IgG (grey). (A) The two lysine residues located on the α-helix of the IgG-binding 
domain (marked in red) have each been modified with the BHHTEGST (green)-Eu3+ (red ball) complex, 
resulting in unfavorable steric interactions in these models. (B) 90° view.
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it was cross-linked to lanthanide-labelled BSA. However in the case of LPG, the detection reagent (PG) is 
genetically-fused to the carrier molecule (linker) which circumvents protein cross-linking. To our knowledge, 
this property is unique to the LPG fusion protein and has not been reported for other detection reagents used for 
TGL microscopy. Traditional carrier molecules also tend to have large masses and varying stabilities that make 
it difficult to maintain their solubility after conjugation. The linker overcomes these complications due to its 
relatively small molecular mass (~10 kDa) and high hydrophilicity. Accordingly, LPG is theoretically 41% more 
soluble than PG (based on their GRAVY index36) which may allow more flexible conjugation procedures and 
higher labelling ratios with less soluble lanthanide binding ligands (e.g., BHHCT).
LA-LPG represents a novel indirect universal detection reagent that rapidly labels virtually any antibody capa-
ble of binding to Protein G with luminescence within seconds. This is property is due to the two different regions 
of LA-LPG. The Protein G region has the ability to bind to a broad range of mammalian IgGs with high affinity 
and binding specificity, allowing for an easy interchange of IgGs for different targets. The linker region of LA-LPG 
functions as a genetically-fused carrier molecule that can be loaded with lanthanide chelates to maximise lumi-
nescence for TGL bioimaging. LA-LPG can be used to directly label antibodies for several applications, e.g., 
bioimaging, cell labelling and detection, and flow cytometry.
Methods
Source of materials. BHHTEGST was synthesised as described previously20. Recombinant LPG was pro-
duced in E. coli and purified by ion exchange chromatography as described previously15. Recombinant PG was 
purchased from Sigma-Aldrich (Australia).
Cells and antibodies. Cryptosporidium oocysts and Giardia cysts, Cryptosporidium monoclonal anti-
bodies CRY104 and CRY104-conjugated to fluorescein isothiocyanate (CRY104-FITC) specific to the walls of 
Cryptosporidium oocysts, and the Giardia monoclonal antibody G203 specific to the walls of Giardia cysts were 
purchased from BTF Pty Ltd (Sydney, Australia). Cells from the cyanobacterium Synechococcus were kindly pro-
vided by Dr Deepa Varkey (Macquarie University).
Conjugation of proteins with BHHTEGST. BHHTEGST contains an N-hydroxysuccinimide ester that 
enables its attachment to proteins via the amino group of lysine residues. Assuming that all of the lysine residues 
were accessible for reaction, each protein (PG without linker, 19 residues and LPG, 27 residues) was conjugated 
with three different molar ratios of the BHHTEGST ligand per lysine residue. This is referred to here as the 
BHHTEGST:Lysine ratio. All conjugation reactions were performed in triplicate. In the conjugation reaction, 
100 μg protein was exchanged into 100 mM NaHCO3, pH 8.5 and then mixed with different molar excesses of 
BHHTEGST. After incubation for 1 h at 37 °C the reaction mixtures were passed through a Sephadex G-25 col-
umn in water to remove excess unconjugated BHHTEGST. The fractions corresponding to labelled conjugates 
were detected using a spectrophotometer (280 and 320 nm), combined and concentrated to 100 μL using an 
Amicon Ultra centrifugal filter (10 kDa cut-off, Millipore).
Relative quantification of BHHTEGST ligands attached to proteins. The UV spectrum of 
BHHTEGST exhibits a maximum absorption at 335 nm and partial absorption at 280 nm, which overlaps with 
that from both proteins (PG and LPG). Thus, to account for the partial absorption of BHHTEGST in conjugated 
proteins, molar extinction coefficients for BHHTEGST were calculated from standard curves at both 320 nm 
and 280 nm as described previously20. The concentration of BHHTEGST was calculated from the absorbance 
of conjugates at 320 nm and the extinction coefficient of BHHTEGST at 320 nm. Then partial absorption of 
BHHTEGST at 280 nm was identified from its standard curve (at 280 nm). The final protein concentration was 
obtained after subtracting the absorbance of BHHTEGST from the absorbance of conjugated protein at 280 nm. 
The average number of BHHTEGST molecules per protein was then determined by dividing the BHHTEGST 
concentration by the protein concentration.
Standard cell-labelling procedure. To couple the conjugates to cell-specific antibodies, each conjugate 
(~2 μg) was mixed with antibody (2 μg) in 100 mM phosphate-buffered saline, pH 7.4 to a final volume of 10 μL 
and incubated for 30 s at room temperature. To label cells, 5 μL of the conjugate-coupled antibodies were loaded 
onto a microscope slide containing fixed target cells and incubated for 1 min at room temperature. Cell fixation 
was carried out by gently drying a 10 μL cell sample on a slide with a hot plate at 40 °C for 20 s. The slide was 
gently rinsed with MilliQ water. Then 3 μL of 22 mM europium(III) chloride (EuCl3) was added to the slide and 
allowed to react with the ligands for 30 s to form the luminescent chelates. The labelled cells were examined using 
bright-field, fluorescence and TGL microscopy.
Microscopy and image analysis. All microscopy and imaging was performed on an Olympus BX51 flu-
orescence microscope with a UPLSAPO 100 X oil immersion objective lens. Colour images were captured by an 
Olympus 12.8 megapixel DP72 camera with a sensor resolution of 4140 × 3096 and stored in the TIFF format. 
To view TGL, a previously described Gated Auto-synchronous Luminescence Detector (GALD) was inserted 
into the DIC slot of the microscope nosepiece3. Cells labelled with luminescence were detected using the GALD 
without any fluorescence filter and exposure times of 3 s. Fluorescence imaging was carried out using a 100 W 
mercury arc lamp and a FITC filter set with 200 ms exposure times. The reduction in exposure time from 3 s to 
200 ms was required to attain comparable image/pixel brightness. All images in this work are as originally sam-
pled and without post processing.
The luminescent labelling of cells was quantified by analysing the raw digital images with the freeware ImageJ 
downloaded from the NIH website (http://rsb.info.nih.gov/ij). In each image, a line-plot was placed across the 
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cells. The 8-bit value of the pixels in the red channel was used to attain the peak intensity and was defined as the 
‘signal’. The mean intensity from a selected section in the darkest region (cell free) was defined as the ‘noise’. These 
values were then used to calculate signal-to-noise ratios (SNR). SNRs were normalised to 1 by dividing the ‘signal’ 
value by the ‘noise’ value (an example is provided in Supplementary Information).
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